Serum Cholesterol Levels and the Risk of Parkinson's Disease
about
Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent PerspectivesNovel subcellular localization for α-synuclein: possible functional consequencesDysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseasesReply: Plasma cholesterol and Parkinson's disease: Is the puzzle only apparent?Integrated molecular landscape of Parkinson's diseaseSerum cholesterol and the progression of Parkinson's disease: results from DATATOP.An exploratory study on CLU, CR1 and PICALM and Parkinson diseaseStatin use and Parkinson's disease in Denmark.Parkin in the regulation of fat uptake and mitochondrial biology: emerging links in the pathophysiology of Parkinson's disease.Total cholesterol and the risk of Parkinson's disease: a review for some new findings.Serum cholesterol and nigrostriatal R2* values in Parkinson's disease.Prospects of statins in Parkinson diseaseParkin is a lipid-responsive regulator of fat uptake in mice and mutant human cells.Apolipoprotein E genotypes and the risk of Parkinson diseaseStatins, plasma cholesterol, and risk of Parkinson's disease: a prospective studyDifferential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on tyrosine hydroxylase and alpha-synuclein in human neuroblastoma SH-SY5Y cells.The oxysterol 27-hydroxycholesterol regulates α-synuclein and tyrosine hydroxylase expression levels in human neuroblastoma cells through modulation of liver X receptors and estrogen receptors--relevance to Parkinson's disease.Lanosterol induces mitochondrial uncoupling and protects dopaminergic neurons from cell death in a model for Parkinson's disease.Prevalence of depression in Parkinson's disease patients in EthiopiaMetabolic markers or conditions preceding Parkinson's disease: a case-control study.Prospective study of plasma urate and risk of Parkinson disease in men and women.Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson diseaseStatin use and the risk of Parkinson diseaseHigher Plasma LDL-Cholesterol is Associated with Preserved Executive and Fine Motor Functions in Parkinson's DiseaseTargets for neuroprotection in Parkinson's diseasePlasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study.Dietary fats, cholesterol and iron as risk factors for Parkinson's disease.Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.Lipid dysfunction and pathogenesis of multiple system atrophy.The emerging role of nutrition in Parkinson's disease.Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis.Diet and age interactions with regards to cholesterol regulation and brain pathogenesis.Parkinson's disease: mitochondrial molecular pathology, inflammation, statins, and therapeutic neuroprotective nutrition.CNS regulation of plasma cholesterol.Targeting metabolic inflammation in Parkinson's disease: implications for prospective therapeutic strategies.Vitamin D and Parkinson's disease.LXR agonists: new potential therapeutic drug for neurodegenerative diseases.The serum lipid profiles of amyotrophic lateral sclerosis patients: A study from south-west China and a meta-analysis.Organophosphate pesticides and PON1 L55M in Parkinson's disease progression.Statins may facilitate Parkinson's disease: Insight gained from a large, national claims database.
P2860
Q26747508-82302647-6FCF-45AA-9A7A-3783DD300586Q26827605-C8425218-FFB4-4BB7-B0B2-0B2C489D8FC5Q27009984-8D851213-133D-47CB-96B8-117023480E2CQ33348468-E0D34833-1F53-4BF0-AADF-E3E8ACA32066Q33767544-9FA8EAB9-8831-4573-B5EE-DF419CA0A2DAQ33996828-629F421C-46AF-443D-B1FF-6E5948876554Q34017691-BB1E76BE-A0D3-47B4-B252-43614B74BFB9Q34020626-3601A502-4404-44D6-9594-D2AFA1578EF5Q34119144-03957E24-9F93-46A3-BA85-E9E111BA8DD1Q34212035-D2B284FD-3162-489B-B5CD-2F335AE9FF01Q34243731-9B503D53-9DA7-45F9-AAC6-7731F251C0CBQ35094028-DE861918-A6EB-48BC-ADB7-AD09ABC008EBQ35208410-58217A53-6B3C-413A-B95C-B722EA7D7690Q35211228-1348294F-E8B0-44FC-9D03-D960D10D3441Q35328089-C1E50C74-570D-4DD2-B203-60F0E4653D81Q35492403-8BC80246-3F41-43A2-B3A7-05015489BE6BQ35552497-9F6E651D-B9E9-4012-B10D-51678F48CFE5Q35754683-507191EF-488E-4F9A-AD8F-1B9A0C9BF814Q36457496-8D7A3184-AC9A-4E5F-8E36-FE904C569189Q36516892-B4A05E4C-2CE6-4DF6-B770-B3956F94D379Q36580376-78A31AF2-AB2E-4AE7-A1A6-D9E9061BB83FQ36667311-2D78DEDA-9D75-4212-B933-47EA48A44C02Q36948690-ADFE17F8-38CA-467E-822E-F76D7AF48B9CQ36983489-790D6FC6-D5E7-4FBB-89C0-0EA54CDDF7BBQ37302453-53E4095F-436F-4265-8B7F-5459FCB4F3AFQ37306126-90B94654-8B5E-42DA-A36A-663B6A8E15ADQ37362433-F5062DEA-7FDA-473B-8206-05074487D2CCQ37506492-2453E5E5-FC89-4972-AEA7-3E5951CE59EEQ37580065-2093A461-C4C8-458D-9031-121F216D43F6Q37622710-4CA93462-262D-4B87-8F52-82AB089D9E92Q37722680-66B41CA1-18FC-4434-8E99-40A8DB1723AFQ37731946-C0C63C4B-7177-4192-A61B-618B7E1A4A0EQ37779428-08ED1C3A-A5A2-4DA9-A0FB-4432E5C80F24Q37897218-9D2558AC-F81C-433D-8668-0CDBE096E30CQ37962621-7D9133F4-ECF0-4A54-869A-E415B1D28D94Q38038831-730F457D-B941-44B6-95C9-2E425F429769Q38102608-99698FB4-8DDD-4F20-B5D0-785B7659F700Q38539827-8A7E974E-8DF0-49E5-8493-7619DB3A75E9Q38660920-AE5BC420-247C-4523-AD90-317A3EA97DD5Q38859501-59ABDF4D-3EED-428F-A551-2D0861FEC935
P2860
Serum Cholesterol Levels and the Risk of Parkinson's Disease
description
im August 2006 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2006
@uk
name
Serum Cholesterol Levels and the Risk of Parkinson's Disease
@en
Serum Cholesterol Levels and the Risk of Parkinson's Disease
@nl
type
label
Serum Cholesterol Levels and the Risk of Parkinson's Disease
@en
Serum Cholesterol Levels and the Risk of Parkinson's Disease
@nl
prefLabel
Serum Cholesterol Levels and the Risk of Parkinson's Disease
@en
Serum Cholesterol Levels and the Risk of Parkinson's Disease
@nl
P2093
P356
P1476
Serum Cholesterol Levels and the Risk of Parkinson's Disease
@en
P2093
Lonneke M. L. de Lau
Monique M. B. Breteler
Peter J. Koudstaal
P304
P356
10.1093/AJE/KWJ283
P407
P577
2006-08-11T00:00:00Z